Advertisement

Co-morbidity in the Severely Mentally Ill: Cardiometabolic Risk Factors, Prevention and Intervention

  • H. L. Millar
  • I. Salloum
  • M. T. Abou-Saleh
Chapter

Abstract

Co-morbidity represents one of the greatest challenges for twenty-first-century medicine. A high prevalence of co-morbidity in the severely mentally ill (SMI) has been well established leading to a significant impact on quality of life, life expectancy and premature death by 15–20 years. The major recognised contributor to excess death is cardiovascular disease.

Known risk factors include smoking, obesity, alcohol and drug misuse and diabetes. The field of knowledge of the linkage between common psychiatric disorders and cardiometabolic risk is growing with a focus on common pathophysiological and inflammatory processes in addition to the already well-recognised cluster of risk factors which have been described in the past as ‘metabolic syndrome’.

International/national guidelines and consensus statements provide the guidance and evidence to optimise screening for and management of risk factors with increasing emphasis on early intervention with lifestyle changes and treatment review.

In this chapter, we have prepared a narrative review of the relevant literature complimented by the authors’ experience of providing holistic care for the SMI. Also we refer to the evidence for shared pathophysiological mechanisms and cardiometabolic risk factors contributing to the high levels of co-morbidity in this population. Finally we make recommendations for screening and treatment outlining effective interventions to improve quality of life and life expectancy.

Keywords

Co-morbidity Severe mental illness Schizophrenia Biological risk factors Cardiovascular disease Metabolic syndrome 

References

  1. 1.
    Prince M, et al. No health without mental health. Lancet. 2007;370(9590):859–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry. 2011;199:441–2.CrossRefPubMedGoogle Scholar
  3. 3.
    Naylor C, et al. Long term conditions and mental health: the cost of co-morbidities. London: Kings fund for Mental Health; 2013.Google Scholar
  4. 4.
    Barnett K, et al. Epidemiology of multimorbidity and implications for healthcare, research and medical education: a cross sectional study. Lancet. 2012;380(9836):37–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Mossavi S, et al. Depression, chronic diseases and decrements in health; results from the world health surveys. Lancet. 2007;370(9590):851–8.CrossRefGoogle Scholar
  6. 6.
    Millar HL, Salloum I. Psychiatric and general co-morbidity. In: Mezzich J, Botbo M, Christodoulou G, Cloninger R, Salloum I, editors. Person centred psychiatry: Springer; 2017.  https://doi.org/10.1007/978-3-319-39724-5.
  7. 7.
    De Hert M, et al. Physical illness in patients with severe mental illness: cardiovascular and metabolic risks. B J Psychopharmacol. 2012;24(8):52–77.Google Scholar
  8. 8.
    De Hert M, et al. Physical illness in patients with severe mental disorders. I prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.CrossRefGoogle Scholar
  9. 9.
    Crepaldi G, Maggi S. The metabolic syndrome: a historical context. Diabetes Voice. 2006;2006(51):9.Google Scholar
  10. 10.
    Ionescu-Tirgoviste C. Treated by Diabet Paulescu. Ed Academei Romane, 2004, pp. 727–749.Google Scholar
  11. 11.
    Zimmet P, Serjentson S. The epidemiology of diabetes mellitus and it relationship with cardiovascular disease. In: Lefebvre PJ, Standl E, editors. New aspect in diabetes. Berlin: DE Gruyer; 1992. p. 5–22.Google Scholar
  12. 12.
    World Health Organisation. Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999.Google Scholar
  13. 13.
    Balkau B, Charles MA. The European Group for the study of insulin resistance (EGIR): comment on the provisional report from the WHO consultation. Diabet Med. 1999;16:442–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Brunner EJ, et al. Social inequality in coronary risk: central obesity and the metabolic syndrome. Diabetologia. 1997;40:1341–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Einhorn D, et al. American College of Endocrinology: insulin resistance syndrome (position statement). Endocr Pract. 2003;9(Suppl. 2):9–21.Google Scholar
  16. 16.
    Kahn R, et al. The metabolic syndrome; a time for a critical appraisal: joint statement for the American Diabetes and Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289–304.CrossRefGoogle Scholar
  17. 17.
    International Diabetes Federation Brussels. The IDF Consensus Worldwide definition of the metabolic syndrome: International Diabetes Federation Brussels; 2005.Google Scholar
  18. 18.
    De Hert M, et al. Physical illness in patients with severe mental disorders II: barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:52–77.CrossRefGoogle Scholar
  19. 19.
    Dipasquale S, et al. Review the dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47:197–207.CrossRefPubMedGoogle Scholar
  20. 20.
    Reis SR, et al. Progress and challenges scaling up physical activity interventions worldwide: stepping up to larger and smarter approaches to get people moving. Lancet. 2016.  https://doi.org/10.1016/S0140-6736(16)30728-0.
  21. 21.
    Zschucke E, et al. Exercise and physical activities in mental disorders; clinical and experimental evidence. J Prev Med Public Health. 2013;46:S12–21.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kelly C, McCreadie R. Cigarette smoking and schizophrenia. Adv Psychiatr Treat. 2000;6:327–31.CrossRefGoogle Scholar
  23. 23.
    Barr RS, et al. The effects of transdermal nicotine on cognition in non-smokers with schizophrenia and non psychotic controls. Neuropsychopharmacology. 2008;33(3):480–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Fernandez Sola C. Cardio-vascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol. 2015;12:576–87.  https://doi.org/10.1038/nrcardio.2015.91.CrossRefPubMedGoogle Scholar
  25. 25.
    Knott CS, et al. All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ. 2015;350:h384.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Malan-Muller S, et al. A systematic review of genetic variants associated with metabolic syndrome with schizophrenia. Schizophr Res. 2016;170:1–17.CrossRefPubMedGoogle Scholar
  27. 27.
    Dipasquale S, et al. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47:197–203.CrossRefPubMedGoogle Scholar
  28. 28.
    Flint J, Munafo M. Schizophrenia: genesis of a complex disease. Nature. 2014;511:412–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Miller BJ, et al. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizoph Relat Psychoses. 2014;7:223–30.CrossRefGoogle Scholar
  30. 30.
    Miller BJ, et al. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;42:92–100.CrossRefGoogle Scholar
  31. 31.
    Naudin J, et al. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res. 1997;26:227–33.CrossRefPubMedGoogle Scholar
  32. 32.
    Fan X, et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149:267–71.CrossRefPubMedGoogle Scholar
  33. 33.
    Walss-Bass C, et al. Clozapine causes oxidation of proteins involved in energy metabolism: possible mechanism for antipsychotic induced metabolic alterations. Int J Neuropsychopharmacol. 2008;11:1097–104.CrossRefPubMedGoogle Scholar
  34. 34.
    Henderson D, et al. Diabetes and psychotic disorders 2: pathophysiological mechanisms of increased cardio-metabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2:452–64.CrossRefPubMedGoogle Scholar
  35. 35.
    Cooper SJ, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with antipsychotic drug treatment. J Psychopharmacol. 2016;30:1–31.CrossRefGoogle Scholar
  36. 36.
    Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ. 2010;340:c2442.  https://doi.org/10.1136/bmj.c2442 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    NICE Guideline [NG56]. Multimorbidity: clinical assessment and management. 2016.Google Scholar
  38. 38.
    NICE Guideline CG181. Cardiovascular disease: risk assessment and reduction including lipid modification. 2014. www.nice.org.uk/guidance/cg181/chapter/1-recommendations Google Scholar
  39. 39.
  40. 40.
    Waterall J, et al. NHS health check: an innovative improvement of local adult health improvement and wellbeing programmes in England. J Public Health. 2015;37(2):177–84.  https://doi.org/10.1093/pubmed/fdv062.CrossRefGoogle Scholar
  41. 41.
    Shiers DE, et al. Positive cardiometabolic health resource: an intervention framework for patients with psychosis and schizophrenia. 2014 updates (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version) (Royal College of Psychiatrists, London) 2014.Google Scholar
  42. 42.
    Peckham E, et al. Smoking Cessation Intervention for Severe Mental III Health Trial (SCIMITAR+): Study protocol for a randomised controlled trail: Trials 2017;18:44.Google Scholar
  43. 43.
    Psychosis with co-existing substance misuse [NG58] 2016: The NICE Guideline on assessment and management in adults and young people.Google Scholar
  44. 44.
    World Health Organisation. Global action plan for the prevention and control of non-communicable diseases (2013–2020). Geneva: WHO; 2013.Google Scholar
  45. 45.
    World Health Organisation. Integrating the response to mental disorders and other chronic diseases in health care systems. Geneva: WHO; 2014.Google Scholar
  46. 46.
    Millar HL, Abou-Saleh MT. Multimorbidity in mentally ill people: the need for a person – centered integrated approach. Int J Pers Cent Med. 2015;5(1):28–33.Google Scholar
  47. 47.
    Wittink MN, et al. Customized care: an intervention to improve communication and health outcomes in multimorbidity. Contemp Clin Trials Commun. 2016;4:214–21.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Millar HL. Physical health in patients with schizophrenia: current knowledge and practical recommendations. J Eur Psychiatric Assoc. 2010;25(Suppl 2):S1–S46.Google Scholar
  49. 49.
    Deakin B, et al. The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. J Psychopharmacol Suppl. 2010;24:8.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • H. L. Millar
    • 1
  • I. Salloum
    • 2
  • M. T. Abou-Saleh
    • 3
  1. 1.Department of PsychiatryThe Carseview CentreDundeeUK
  2. 2.Division of Alcohol and Drug Abuse: Treatment and Research, Department of PsychiatryUniversity of Miami Miller School of MedicineMiamiUSA
  3. 3.St George’s, University of LondonLondonUK

Personalised recommendations